The investigational new drug MB-110 developed by Microbio Co., Ltd. was approved for phase I clinical trials by US FDA on December 18, 2015.

The FDA approved the application for human clinical trials for MB-110, a NS5A inhibitor developed for the treatment of chronic hepatitis C infection, specifically for patients with genotypes 1b, 2a and 3a, which covers the majority of patient populations in China, Korea and Japan. In-vitro cell-based studies have demonstrated its superior efficacy in genotype 1b, 2a and 3a with great therapeutic window and synergistic effect when combined with various anti-HCV drugs.